Viscosupplementation Market Size & Growth Forecast 2027–2036, By Segments (End-use, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Viscosupplementation Market size was over USD 6.2 billion in 2026 and is likely to grow at a 5.89% CAGR between 2027 and 2036, exceeding USD 10.99 billion by 2036. The industry revenue for 2027 is assessed at USD 6.51 billion.
Get more details on this report
Request Free Sample ReportViscosupplementation Market Intelligence Snapshot
Regional Market Dynamics
- Asia Pacific accounted for 48.55% of the market in 2026, supported by a large patient pool, sustained osteoarthritis treatment volumes, and expanding healthcare access across major economies.
- Europe is expected to expand at an 11.07% CAGR as aging populations, established musculoskeletal care pathways, and wider adoption of injection-based therapies increase demand for non-surgical osteoarthritis management.
Segment Momentum
- Orthopedic Clinics/ASCs held a 61.17% share in 2026 because they efficiently manage evaluation, injection procedures, and follow-up care within specialized outpatient settings, supporting streamlined treatment pathways.
- Single Injection led with a 46.05% share and the strongest growth due to its one-visit treatment approach. Reduced appointment requirements and greater convenience make it highly attractive to both providers and patients.
Market Expansion Drivers
- Rising osteoarthritis prevalence and aging population increasing demand for joint pain therapies.
- Preference for minimally invasive single-injection treatments expanding outpatient adoption.
- Expanding reimbursement coverage and early-stage clinical adoption of viscosupplementation therapies.
Leading Market Participants
- Key companies in the viscosupplementation market include DePuy Synthes (United States), Fidia Farmaceutici S.p.A. (Italy), Sanofi S.A. (France), Smith & Nephew plc (United Kingdom), Anika Therapeutics, Inc. (United States), Seikagaku Corporation (Japan), Zimmer Biomet Holdings, Inc. (United States), Ferring Pharmaceuticals B.V. (Switzerland), Lifecore Biomedical, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.2 billion
- 2027 Estimated Market Size: USD 6.51 billion.
- Projected Market Size: USD 10.99 billion by 2036
- Growth Forecast: 5.89% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: Asia Pacific
- High-Growth Regional Hub: Europe
- Core Revenue Segment: Orthopedic Clinics/ASCs (End-use) | Single Injection (Product)
- Emerging Opportunity Segment: Orthopedic Clinics/ASCs (End-use) | Single Injection (Product)
Market Growth Drivers and Industry Trends
Rising osteoarthritis prevalence and aging population increasing demand for joint pain therapies
An expanding aging population and the increasing prevalence of osteoarthritis are supporting the viscosupplementation market by creating greater demand for therapies aimed at managing joint pain and improving mobility. Osteoarthritis commonly affects weight-bearing joints and can limit daily activities as symptoms progress, increasing the need for treatment options that can be incorporated into patient care. Viscosupplementation provides an established therapeutic approach for joint-related symptoms, supporting its use among patients seeking non-surgical management of osteoarthritis-associated discomfort.
Preference for minimally invasive single-injection treatments expanding outpatient adoption
Growing preference for convenient and minimally invasive care is strengthening the viscosupplementation market, particularly as patients and healthcare providers seek treatment approaches that can be administered without surgical intervention. Single-injection formulations can reduce the number of treatment visits compared with multi-injection regimens, making therapy more convenient within outpatient settings. Their administration within routine clinical environments can also simplify treatment scheduling while supporting patient acceptance of joint pain management options that require limited procedural intervention.
Expanding reimbursement coverage and early-stage clinical adoption of viscosupplementation therapies
Broader reimbursement availability can improve access to viscosupplementation by reducing financial barriers for eligible patients and supporting treatment consideration within routine clinical care. At the same time, early-stage clinical adoption of viscosupplementation therapies can encourage healthcare providers to incorporate these options into treatment pathways for appropriate patients with joint pain. Greater familiarity among clinicians and patients, together with improved coverage conditions, can facilitate wider utilization across outpatient and orthopedic care settings.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising osteoarthritis prevalence and aging population increasing demand for joint pain therapies | 2.40% | High | Asia Pacific, Europe, North America | High | Near Term |
| Preference for minimally invasive single-injection treatments expanding outpatient adoption | 2.10% | High | North America, Europe | Medium | Near Term |
| Expanding reimbursement coverage and early-stage clinical adoption of viscosupplementation therapies | 1.70% | Moderate | Asia Pacific | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
Asia Pacific (Largest Region)
Asia Pacific held the largest share of the viscosupplementation market, representing 48.55% in 2026. The region’s leading position is supported by a growing aging population, rising prevalence of osteoarthritis, and increasing awareness of non-surgical approaches for managing joint pain. Improving healthcare infrastructure and expanding access to orthopedic care are supporting greater adoption of viscosupplementation procedures. In addition, growing healthcare expenditure and improving availability of minimally invasive treatment options are strengthening demand across major regional healthcare markets.
Europe (Fastest-Growing Region)
Europe is the fastest-growing region, driven by increasing demand for minimally invasive osteoarthritis treatments and greater attention to preserving mobility among aging populations. Improvements in healthcare access and growing physician familiarity with injectable therapies are supporting wider use of viscosupplementation. The region’s emphasis on patient-centered care, rehabilitation, and alternatives to more invasive orthopedic interventions is also contributing to market development, while continued improvements in clinical practice are encouraging adoption across healthcare systems.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Conservative Clinical AdoptionGermany shows cautious adoption of viscosupplementation therapies, with usage concentrated in orthopedic specialists and private clinics. German healthcare providers prioritize evidence-based treatment protocols and cost-effectiveness in managing degenerative joint conditions.
France 🇫🇷
Reimbursed Therapy PathwaysFrance supports viscosupplementation usage through structured clinical pathways within orthopedic care systems. Healthcare providers in France focus on regulated administration and patient selection criteria aligned with national treatment guidelines for osteoarthritis.
Italy 🇮🇹
Specialist Orthopedic UseItaly’s viscosupplementation market is concentrated in orthopedic specialist settings addressing knee and joint degeneration cases. Italian clinicians emphasize conservative treatment approaches that support pain management and functional improvement before surgical consideration.
Japan 🇯🇵
Aging Population CareJapan’s viscosupplementation demand is influenced by a rapidly aging population and increasing prevalence of knee osteoarthritis. Clinicians in Japan focus on joint preservation therapies that delay surgical intervention and support mobility maintenance in elderly patients.
South Korea 🇰🇷
Aesthetic Orthopedic ClinicsSouth Korea integrates viscosupplementation into private orthopedic and sports medicine clinics offering advanced joint care services. Providers in South Korea are expanding non-surgical treatment options to meet growing demand from active and aging populations.
United States 🇺🇸
Orthopedic Treatment ExpansionThe viscosupplementation market in the U.S. is supported by rising use in osteoarthritis management across orthopedic and sports medicine clinics. Providers in the U.S. are emphasizing minimally invasive joint therapies alongside outpatient treatment models and expanding patient access through specialty care networks.
Viscosupplementation Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Orthopedic Clinics/ASCs (Largest & Fastest-Growing Segment)
Orthopedic Clinics/ASCs dominated the viscosupplementation market and represented the fastest-growing end-use segment, accounting for a 61.17% share in 2026. Their strong position is supported by the growing use of minimally invasive orthopedic interventions and the suitability of outpatient settings for viscosupplementation procedures. These facilities can provide focused musculoskeletal care with efficient treatment workflows, supporting convenient patient access and timely administration. Increasing preference for specialized orthopedic services and streamlined procedural environments continues to reinforce demand within this end-use segment.
Product Segment Analysis: Single Injection (Largest & Fastest-Growing Segment)
The single injection segment held the leading position in the viscosupplementation market and was also the fastest-growing product segment, representing a 46.05% share in 2026. Its adoption is supported by the convenience of completing treatment through a single administration, which can simplify scheduling and improve patient adherence compared with regimens requiring multiple visits. Healthcare providers can also benefit from more efficient treatment delivery and reduced procedural burden, while patients may favor approaches that minimize repeated clinical appointments. These advantages are strengthening the role of single-injection products across viscosupplementation treatment settings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Hospitals, Orthopedic Clinics/ASCs | Orthopedic Clinics/ASCs | Orthopedic Clinics/ASCs |
| Product | Single Injection, Three Injection, Five Injection | Single Injection | Single Injection |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Key companies in the viscosupplementation market:
1. DePuy Synthes (United States)
2. Fidia Farmaceutici S.p.A. (Italy)
3. Sanofi S.A. (France)
4. Smith & Nephew plc (United Kingdom)
5. Anika Therapeutics Inc. (United States)
6. Seikagaku Corporation (Japan)
7. Zimmer Biomet Holdings Inc. (United States)
8. Ferring Pharmaceuticals B.V. (Switzerland)
9. Lifecore Biomedical Inc. (United States)
10. F. Hoffmann-La Roche Ltd (Switzerland)
The viscosupplementation market is evolving through continuous efforts to improve treatment durability, injection efficiency, and patient comfort in joint care therapies. Participants are prioritizing the development of advanced formulations with enhanced viscosity profiles and longer-lasting therapeutic benefits. Strategic collaborations supporting clinical research and innovation are also contributing to the expansion of next-generation viscosupplementation solutions across orthopedic applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| DePuy Synthes (United States) | |||||||
| Fidia Farmaceutici S.p.A. (Italy) | |||||||
| Sanofi S.A. (France) | |||||||
| Smith & Nephew plc (United Kingdom) | |||||||
| Anika Therapeutics Inc. (United States) | |||||||
| Seikagaku Corporation (Japan) | |||||||
| Zimmer Biomet Holdings Inc. (United States) | |||||||
| Ferring Pharmaceuticals B.V. (Switzerland) | |||||||
| Lifecore Biomedical Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Cipla | Dec-25 | Cipla launched Ciplostem, a DCGI-approved cell therapy for knee osteoarthritis in India, in partnership with Stempeutics Research. This launch signifies the company’s strategic entry into orthobiologic medicine, providing a long-term, regenerative therapeutic alternative to traditional hyaluronic acid-based viscosupplementation for patients suffering from degenerative knee osteoarthritis. |
| Anika Therapeutics | Mar-25 | Anika Therapeutics finalized the divestiture of Parcus Medical to Medacta Group. This strategic portfolio optimization allows Anika to concentrate its resources and capital on its core hyaluronic acid-based pain management solutions, strengthening its competitive focus within the viscosupplementation and regenerative medicine segments. |
| Bioventus | Oct-24 | Bioventus divested its Advanced Rehabilitation segment to Accelmed Partners for USD 45 million. This divestiture reflects a broader strategic realignment, allowing the company to streamline operations and focus its investment capacity on its core musculoskeletal and orthobiologic product lines, including its flagship HA-based viscosupplementation offerings. |
| Fidia Farmaceutici | Sep-24 | The U.S. FDA approved Hymovis for the treatment of knee osteoarthritis in patients who have failed to respond to first-line therapy. The approval, based on clinical non-inferiority to Hyalgan, introduces a new, high-viscosity cross-linked hyaluronic acid option to the U.S. market, expanding the competitive landscape for intra-articular injections. |
| IBSA Group | Feb-24 | IBSA UK launched the SINOVIAL range for osteoarthritis treatment. Utilizing proprietary NAHYCO technology, the product combines high and low molecular weight hyaluronic acid to enhance joint lubrication. This expansion underscores IBSA’s commitment to advancing HA-based therapeutic formulations to address the evolving clinical needs of osteoarthritis patients in the UK. |
| Zimmer Biomet | Jan-24 | Zimmer Biomet launched VISCO-3, a three-injection high molecular weight hyaluronate treatment for moderate-stage knee osteoarthritis. Clinical data demonstrated a 52% reduction in patient pain at 12 weeks with relief lasting up to six months, reinforcing the company’s position in the global market for intermediate-term osteoarthritis pain management. |
| Juniper Biologics | Apr-22 | Juniper Biologics and Kolon Life Science entered a licensing agreement to develop and commercialize TissueGene-C, an investigational cell-mediated gene therapy for knee osteoarthritis. This partnership represents a strategic move toward incorporating advanced biological alternatives into the standard of care for joint degeneration, potentially disrupting traditional viscosupplementation treatment pathways. |
| Avanos Medical | Dec-21 | Avanos Medical acquired OrthogenRx to expand its chronic pain management portfolio. The acquisition granted Avanos access to established viscosupplementation therapies for knee osteoarthritis pain, providing the company with an immediate footprint in the OA market and enhancing its ability to offer comprehensive, non-surgical solutions to pain management specialists. |
| Seikagaku Corporation | Aug-21 | Seikagaku Corporation launched Hylink, a single-injection cross-linked hyaluronate hydrogel, in the Taiwan market. Developed in partnership with TCM Biotech, this advanced viscosupplement is designed to improve the viscoelasticity of the synovial fluid, providing long-lasting symptomatic relief for knee osteoarthritis patients and enhancing Seikagaku’s presence in the Asian orthopedic market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Viscosupplementation Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Severity | Mild Osteoarthritis, Moderate Osteoarthritis, Severe Osteoarthritis |
| Patient Age Group | Adults Under 50, Adults Aged 50–64, Adults Aged 65 and Above |
| Reimbursement Coverage | Publicly Reimbursed, Privately Reimbursed, Self-Pay |
Viscosupplementation Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Osteoarthritis Treatment Pathway Analysis |
|
| Clinical Adoption & Physician Preference Study |
|
| Patient Access & Treatment Utilization Analysis |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much revenue does the viscosupplementation market generate?
What are the growth projections for the viscosupplementation industry?
Which treatment trends are accelerating adoption in the viscosupplementation market?
How are reimbursement expansion and clinical adoption influencing the viscosupplementation market?
Why are Orthopedic Clinics/ASCs the leading end-use segment in the viscosupplementation market?
What makes Single Injection the fastest-growing product segment in the viscosupplementation market?
Why is Asia Pacific the leading region in the viscosupplementation market?
What factors are accelerating viscosupplementation market growth in Europe?
What are the prominent companies operating in the viscosupplementation landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook